Brief: Biora Therapeutics Licenses Preeclampsia Rule-Out Test For Commercial Development
29/11/2022 14:03
Nov 29 (Reuters) - Biora Therapeutics Inc BIOR.O :
* BIORA THERAPEUTICS LICENSES PREECLAMPSIA RULE-OUT TEST FOR
COMMERCIAL DEVELOPMENT
Source text for Eikon: ID:nGNX8kprzK
Further company coverage: BIOR.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Biora Therapeutics
See all newsBiora Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Biora Therapeutics Provides Corporate Update And Reports Third Quarter 2024 Financial Results
Biora Therapeutics Inc expected to post a loss of $3.85 a share - Earnings Preview
Biora Therapeutics Inc expected to post a loss of $3.85 a share - Earnings Preview
Brief: Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules